Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2022-01-27 Board/Management Inform…
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the approval of cash bonus payments to named executive officers for the 2021 fiscal year, including amounts and titles. This corresponds to an announcement related to changes or updates in management compensation or executive arrangements. The key section is Item 5.02, which relates to departure or appointment of directors or officers and compensatory arrangements. This fits best under the category of Board/Management Information (MANG), as it announces management compensation decisions and executive officer information. The document length is 3752 characters, which is short and focused on this announcement, not a full report or detailed financial statements. Therefore, the classification is MANG with high confidence.
2022-01-27 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-01-27 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-01-25 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement related to contingent value rights (CVR) following the expiration of a specified condition. It includes no financial statements or detailed financial analysis but rather a specific event disclosure. The document length is 4111 characters, which is relatively short and consistent with an 8-K current report. This type of filing is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Earnings Release, or Capital Update.
2022-01-14 English
PRIMARY DOCUMENT
Director's Dealing
2021-11-17 English
PRIMARY DOCUMENT
Director's Dealing
2021-11-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.